did the fda ban semaglutide Compounded GLP-1 ban: What providers need to know Compounded Semaglutide & Tirzepatide 2025:

Current evidence suggests that GLP-1 receptor agonists do not appear to cause disproportionate muscle loss compared to equivalent weight loss achieved through other methods, though individual responses may vary

Others benefit from longer-term maintenance therapy, particularly those with strong genetic components to their weight challenges

Individuals with Obesity or Type 2 Diabetes: Likely to benefit from both the metabolic and alcohol-reducing effects

So you can better understand how this works practically, you can hear directly from three customers who found success and reclaimed their lives on personalized treatment plans through our platform